2018
Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns
Effendi M, Stutsky M, Curran C, Owusu K, Lee A. Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns. Blood 2018, 132: 2284. DOI: 10.1182/blood-2018-99-119379.Peer-Reviewed Original ResearchLow molecular weight heparinAnti-Xa levelsAnti-Xa level monitoringRetrospective chart reviewNon-therapeutic levelsEnoxaparin doseAdult patientsChart reviewCommon indicationDose adjustmentNursing staffBody weightDrug monitoringTherapeutic monitoringAbnormal levelsStudy periodExtreme body weightRoutine laboratory monitoringRenal replacement therapyCertain patient populationsMolecular weight heparinFavorable pharmacokinetic profileRisk of toxicityClinical decision makingEnoxaparin therapy
2015
Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy
Stutsky M, Reardon D, Lee A. Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy. Blood 2015, 126: 3275. DOI: 10.1182/blood.v126.23.3275.3275.Peer-Reviewed Original ResearchAnti-Xa levelsAnti-Xa monitoringLMWH doseLow molecular weight heparin therapyAbnormal body mass indexActions of providersWeight heparin therapyAcute kidney injuryChronic kidney diseaseHigh-risk patientsRetrospective chart reviewLong-term therapyBody mass indexClinical practice patternsFactor Xa inhibitorsNon-therapeutic levelsEnoxaparin doseHematology consultHeparin regimensTherapeutic LMWHHeparin therapyKidney injuryLMWH therapyRenal dysfunctionVenous thromboembolism